ALEC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alector Inc (ALEC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown a recent price increase, the technical indicators and lack of significant positive catalysts do not support a confident long-term investment decision. The absence of strong financial performance data and limited analyst consensus further suggest caution.
The technical indicators for ALEC are mixed. The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 61.381, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 1.776 and 1.878, while support levels are at 1.448 and 1.346. The stock has an 80% chance of a minor increase (1.2%) in the next day but shows a potential decline (-2.15%) over the next month.
Morgan Stanley raised the price target to $2, and Cantor Fitzgerald upgraded the stock to Overweight, citing potential in the Alector Brain Carrier platform for neurodegenerative drug delivery. The recent price increase of 12.18% in regular trading and 2.31% post-market may indicate short-term positive sentiment.
The failure of the AL101 Phase 2 PROGRESS-AD trial is a significant negative event. The MACD and moving averages indicate bearish momentum. No recent news or significant trading trends from hedge funds or insiders. No congress trading data available.
No financial data is available for analysis, making it difficult to assess the company's growth trends or financial health.
Analyst sentiment is mixed. Morgan Stanley maintains an Underweight rating despite raising the price target, while Cantor Fitzgerald is optimistic about the company's potential in neurodegenerative drug delivery. However, the lack of consensus and the firm's recent trial failure weigh on the outlook.
